Clinical Trial Update: Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice

View source ↗

Summary

Post-authorization safety study evaluating the real-world safety of tolvaptan (Samsca) in patients with hyponatremia, including SIADH-related hyponatremia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia
• Syndrome of Inappropriate Antidiuretic Hormone Secretion

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Otsuka Frankfurt Research Institute GmbH | Conditions: SIADH, Non-SIADH Hyponatremia | Status: UNKNOWN